Pennsylvania is currently home to 3461 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Philadelphia, Pittsburgh, Hershey and Allentown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS
NCT05267821
Recruiting
The TRIPS study is a prospective, multi-center, double-blind, adaptively randomized, placebo-controlled clinical trial of the drug anakinra for reversal of moderate to severe hyperinflammation in children with sepsis-induced multiple organ dysfunction syndrome (MODS).
Gender:
All
Ages:
Between 1 day and 17 years
Trial Updated:
02/07/2023
Locations: Pennsylvania State University, Hershey, Pennsylvania
Conditions: Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome (MODS)
Register for Updates
ACDF Using Structural Allograft vs. Tritanium C
NCT04388332
Recruiting
This is an observational, descriptive, prospective and retrospective data collection study. The purpose of this study is to observe radiographic outcomes of patients who will undergo anterior cervical discectomy and fusion (ACDF) utilizing Tritanium C (Stryker Spine). The rate of fusion success and adverse events will be compared retrospectively to patients who underwent instrumented ACDF utilizing structural allograft bone with plates.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
02/07/2023
Locations: Allegheny Health Network, Pittsburgh, Pennsylvania
Conditions: Degenerative Disc Disease
Register for Updates
Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers
NCT03748186
Recruiting
Phase 1 trial to study the safety, pharmacokinetics and preliminary efficacy of STRO-002 given intravenously every 3 weeks.
Gender:
Female
Ages:
18 years and above
Trial Updated:
02/07/2023
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Ovarian Cancer, Ovarian Carcinoma, Ovary Cancer, Endometrial Cancer, Endometrioid Adenocarcinoma, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Register for Updates
Vaginal Estrogen and Pelvic Floor Physical Therapy in Women With Symptomatic Mild Prolapse
NCT01648751
Recruiting
This is a randomized controlled trial in which women with symptomatic mild pelvic organ prolapse undergoing Pelvic Floor Physical Therapy (PFPT) receive vaginal estrogen versus placebo to see if a combined approach to treatment leads to improvement in clinical outcomes. The investigators predict that PFPT in combination with vaginal estrogen will lead to decreased pelvic floor symptoms and improved anatomical support corroborated by biomarker data.
Gender:
Female
Ages:
Between 40 years and 80 years
Trial Updated:
02/07/2023
Locations: Magee-Womens Hospital, University of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Pelvic Organ Prolapse
Register for Updates
EXCOR Active Driving System for the EXCOR Pediatric VAD IDE Study
NCT05610787
Recruiting
The purpose of this study is to evaluate the device performance and monitor the safety and effectiveness of the Berlin Heart EXCOR Active Driving System while being used with the approved EXCOR Pediatric Ventricular Assist Device. EXCOR Active Driving System is intended for use with the approved EXCOR Pediatric VAD. The EXCOR Pediatric VAD is intended to provide mechanical circulatory support as a bridge to cardiac transplantation for pediatric patients. Pediatric candidates with severe isolat... Read More
Gender:
All
Ages:
21 years and below
Trial Updated:
02/06/2023
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Heart Failure, Transplant; Failure, Heart, Congenital Heart Disease
Register for Updates
Validation of a Salivary miRNA Diagnostic Test for ASD
NCT05418023
Recruiting
This study involves sample collection to identify biomarkers relating to Autism Spectrum Disorder(ASD) in the saliva of children who are between the ages of 18 months to 6 years and 11 months. Participants will at each timepoint have a non-invasive saliva swab collected and complete a brief demographic and medical history questionnaire as well. Children in the pediatric/provider setting who will receive a referral for an ASD diagnosis because they were determined to have a suspicion of developin... Read More
Gender:
All
Ages:
Between 18 months and 7 years
Trial Updated:
02/06/2023
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Autism Spectrum Disorder, Developmental Delay
Register for Updates
SLSMDS Natural History Study
NCT05029843
Recruiting
The Single Large-Scale mtDNA Deletion Sydrome: Natural History Study (PS-NHS) aims to collect data on standardized clinical outcomes, store data on the Champ Foundation Registry (CFR) and make this data available to researchers, clinicians, and industry partners who are studying SLSMDS to answer questions regarding the disease, including its causes, potential treatments, and other topics. A secondary aim is to analyze the data to understand research questions relating to the natural history of S... Read More
Gender:
All
Ages:
All
Trial Updated:
02/06/2023
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Pearson Syndrome, Single Large Scale Mitochondrial DNA Deletion Syndromes (SLSMDS)
Register for Updates
The PROMISE Study: Duavee in Women With DCIS
NCT02694809
Recruiting
The main purpose of this study is to determine if taking the study drug, conjugated estrogens/bazedoxifene (Duavee®) causes any changes in the proliferation markers within the breast tissue of the study subjects. The study drug is approved by the US Food and Drug Administration in healthy postmenopausal women to treat certain symptoms of menopause such as hot flashes. Since it is not approved in women with DCIS, its use in this study is experimental. This study will also look at whether taking t... Read More
Gender:
Female
Ages:
Between 18 years and 79 years
Trial Updated:
02/06/2023
Locations: Thomas Jefferson University, Philadelphia, Pennsylvania
Conditions: Ductal Breast Carcinoma In Situ, Postmenopausal
Register for Updates
Apixaban for the Acute Treatment of Venous Thromboembolism in Children
NCT02464969
Recruiting
To assess the safety and descriptive efficacy of apixaban in pediatric subjects requiring anticoagulation for the treatment of a VTE.
Gender:
All
Ages:
Between 0 days and 17 years
Trial Updated:
02/06/2023
Locations: The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Venous Thromboembolism
Register for Updates
Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Neurostimulation
NCT04950894
Recruiting
Multi-center, open-label, prospective, randomized clinical trial of the aura6000(R) System for the reduction of apnea and hypopneas in adult patients with moderate to severe obstructive sleep apnea who have failed or are unwilling to use positive airway pressure treatment.
Gender:
All
Ages:
22 years and above
Trial Updated:
02/02/2023
Locations: Penn State Health, Hershey, Pennsylvania
Conditions: Obstructive Sleep Apnea, OSA, Apnea, Apnea, Obstructive, Apnea, Obstructive Sleep, Apnea+Hypopnea, Hypopnea, Sleep
Register for Updates
Stress Hydrocortisone In Pediatric Septic Shock
NCT03401398
Recruiting
SHIPSS is a multi-institutional, prospective, controlled, randomized, double-blinded interventional trial that will examine the potential benefits and risks of adjunctive hydrocortisone prescribed for children with fluid and vasoactive-inotropic refractory septic shock. It is hypothesized that adjunctive hydrocortisone will significantly reduce the proportion of children with poor outcomes, defined as death or severely impaired health-related quality of life (HRQL), as assessed at 28 days follo... Read More
Gender:
All
Ages:
Between 1 month and 17 years
Trial Updated:
02/02/2023
Locations: Penn State Milton S. Hershey Children's Hospital, Hershey, Pennsylvania
Conditions: Septic Shock
Register for Updates
CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer
NCT05210283
Recruiting
The CORRECT - MRD II study will prospectively enroll patients who have undergone complete surgical resection for stage II or III colorectal cancer. Patients will be followed for a minimum of 3 years and up to 5 years for recurrence.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/01/2023
Locations: UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
Conditions: Colorectal Cancer
Register for Updates